Table 1.
Patient Demographics and Preindex Healthcare Treatment and Resource Use, by Drug: On-Treatment Sample
| Variable | Aripiprazole (N = 3690) | Olanzapine (N = 3038) | Quetiapine (N = 7936) | Risperidone (N = 2997) | Ziprasidone (N = 1515) |
|---|---|---|---|---|---|
| Mean age, yrs (SD) | 38.50 (12.7) | 40.16 (12.8)a | 39.01 (12.2)a | 39.24 (12.9)a | 39.90 (12.2)a |
| Male, N (%) | 1151 (31.2) | 1423 (46.8)a | 2968 (37.4)a | 1241 (41.4)a | 454 (30.0) |
| Index year, N (%) | |||||
| 2003 | 130 (3.5) | 523 (17.2)a | 404 (5.1)a | 320 (10.7)a | 70 (4.6)a |
| 2004 | 270 (7.3) | 630 (20.7)a | 860 (10.8)a | 574 (19.2)a | 169 (11.2)a |
| 2005 | 512 (13.9) | 545 (17.9)a | 1306 (16.5)a | 550 (18.4)a | 280 (18.5)a |
| 2006 | 828 (22.4) | 541 (17.8)a | 1777 (22.4)a | 658 (22.0)a | 352 (23.2)a |
| 2007 | 1005 (27.2) | 507 (16.7)a | 2299 (29.0)a | 595 (19.9)a | 397 (26.2)a |
| 2008 | 945 (25.6) | 292 (9.6)a | 1290 (16.3)a | 300 (10.0)a | 247 (16.3)a |
| Mean Charlson comorbidity index (SD) | 0.32 (0.82) | 0.34 (0.96) | 0.34 (0.88) | 0.34 (0.90) | 0.38 (0.88)a |
| All-cause hospitalization, N (%) | 831 (22.5) | 922 (30.3)a | 2412 (30.4)a | 981 (32.7)a | 489 (32.3)a |
| Mental health–related hospitalization, N (%) | 757 (20.5) | 873 (28.7)a | 2246 (28.3)a | 914 (30.5)a | 465 (30.7)a |
| Diabetes, N (%) | 302 (8.2) | 140 (4.6)a | 551 (6.9)a | 214 (7.1) | 148 (9.8) |
| Hyperlipidemia, N (%) | 696 (18.9) | 538 (17.7) | 1413 (17.8) | 559 (18.7) | 311 (20.5) |
| Glucose testing conducted, N (%) | 1360 (36.9) | 1108 (36.5) | 2958 (37.3) | 1068 (35.6) | 603 (39.8)a |
| Lipid testing conducted, N (%) | 717 (19.4) | 552 (18.2) | 1508 (19.0) | 535 (17.9) | 329 (21.7) |
| Use of mood stabilizer, N (%) | 1721 (46.6) | 1037 (34.1)a | 3342 (42.1)a | 1187 (39.6)a | 698 (46.1) |
a
P <.05 versus aripiprazole.
SD indicates standard deviation.